Navigation Links
SECO and IBD Partner for the Realization of Respira Non-invasive Pulmonary Ventilators

SECO, a leading company in the hi-tech sector, specializing in computer miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento SGR, today announced a partnership with IBD, an innovative Italian company operating in the biomedical market, for the development of Respira, a new non-invasive pulmonary ventilator created in response to the current health emergency of the COVID-19 pandemic. Respira was developed by a team of Italian doctors with direct and extensive experience on the front lines of the pandemic.

SECO’s technological capabilities in combination with IBD’s knowledge and competencies in the medical sector, have brought Respira to life. Respira is a compact and portable high-flux, pulmonary ventilator for patients with COVID-19-related pneumonia in both domestic and hospital environments. The new ventilators, which bypass the need for invasive intubation, are equipped with touchscreen displays for easy and intuitive use.

“It gives me great pride that in such difficult times two Italian industry leaders like SECO and IBD have brought together their technological competencies to provide a tangible contribution to the healthcare system and its patients, through an innovative, non-invasive and portable solution for pulmonary ventilation,” said Massimo Mauri, Chief Executive Officer for SECO.

Established in 2014, IBD designs and develops biomedical devices with the goal of innovating on portability, user-friendliness for healthcare personnel and patients, for both domestic and hospital applications. Following the concepts of “Less is More” and Lean Startup, IBD has developed, in a timely fashion and with limited resources, extremely innovative biomedical devices,” said Dr. Corrado Ghidini, MD of IBD. “As Italy has always been a leader in the biomedical field, the partnership with SECO provides the perfect complement for the realization of an industrial plan that can contribute in relaunching Italy on a global scale.”

In addition to ventilating patients affected by COVID-19 without intubation, Respira can also be used in immunodepression cases as well as those that require oxygenation in both pre-and post-intensive care. Designed in Italy and manufactured in the USA, the new pulmonary ventilators are expected to start deliveries between late May and early June 2020.

Assisted pulmonary ventilation is considered by most to be the only effective therapy for those patients affected by COVID-19-related respiratory deficiency. The innovative ventilators developed by SECO and IBD will contribute in increasing the availability of these fundamental medical devices, currently only available in limited amounts, at very high prices and exclusively used by intubated patients in ICUs.

About SECO
SECO is an Italian group with a leading global position in the sector of embedded technology and Internet of Things (IoT). Since 1979, it has been designing and producing embedded systems – industrial computers that are integrated into a client’s machine or tool, activating its functions and permitting interaction through touch/video interfaces. SECO collaborates with a broad network of strategic suppliers in the international high-tech panorama (including Intel®, AMD, NXP, NVIDIA®, Wind, and Telenor), as well as with universities, research centers and innovative start-ups, and operates on a global scale with offices in Italy, Germany, the U.S., India and Taiwan, employing more than 380 people. The industrial sectors in which SECO products are utilized range from biomedicine to wellness, industrial automation to transportation, and it has clients that are market leaders, such as Cimbali, Esaote, Evoca, and Technogym.

About FII Tech Growth
FII Tech Growth, with a fundraising target of €150 million, is the first Italian late-stage technology investment equity fund. It is managed by Fondo Italiano d’Investimento SGR and is dedicated to invest in the growth of small and medium-sized Italian companies with high-tech business models. The fund announced its first closing in September 2017 with Cassa Depositi e Prestiti as cornerstone investor. Fondo Italiano d'Investimento SGR currently manages a total of eight investment funds, dedicated to institutional investors, for a total of about Euro 3 billion of Assets Under Management.

IBD is a biomedical devices manufacturer company conceived in London and founded in Italy in 2014. Guided by a team with +10 years of experience in dialysis and medical device design, IBD has raised so far over € 1 million in funding by angel investors and grants. It is now facing a new round of funding.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Box, ComplianceQuest and USDM Life Sciences Partner to Launch Unify Compliance Cloud
2. Former FDA Branch Chief of Radiation Programs Joins NDA Partners as Expert Consultant
3. OU Health Sciences Center Partners With Pure MHC on COVID-19 Vaccine Project
4. Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra
5. Kerafast Partners with The Good Food Institute to Facilitate Access to Cell Lines for Developing Sustainable Meat and Seafood
6. Jason Burke Joins CREO, Inc. as Partner to Head Analytics and Data Sciences Practice
7. Asymmetrex Partners in Manufacturing USA Institute
8. R3 Stem Cell Now Offering Complimentary Overnight Biologic Shipping for Practice Network Partners
9. Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
10. Marque D. Todd, MS, DVM, DABT, Joins NDA Partners as Regulatory Toxicology Expert
11. Project Lifeline Community Partner, Researcher to be Honored at NACDS Foundation Dinner for Opioid Abuse Prevention Work
Post Your Comments:
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable ... testing operations in the fight against the COVID-19 pandemic in Zambia. , One ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World has ... Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and ... elite awards program, highlighting outstanding examples of how technology innovations and strategic initiatives ...
(Date:6/28/2020)... ... 25, 2020 , ... The Indoor Lab, a leading provider of sensor solutions ... all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology ... business will provide a health performance index system that scores all aspects of compliance ...
(Date:6/23/2020)... ... , ... Kerafast Inc. , developers of an online ... of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by ... entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment. , ...
Breaking Biology Technology: